



Evomela® (melphalan) – Indication withdrawal

- On August 9, 2021, the [FDA approved](#) the voluntary removal of Acrotech Biopharma's [Evomela \(melphalan\)](#) indication for palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.
- Evomela remains approved for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma.
- Evomela carries a boxed warning for severe bone marrow suppression, hypersensitivity, and leukemogenicity.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.